Hanna Piwowarska-Bilska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hanna Piwowarska-Bilska has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Bożena Birkenfeld
Department of Nuclear Medicine , Pomeranian Medical University in Szczecin , Szczecin , Poland
34 shared publications - Maria Listewnik
Department of Nuclear Medicine, Pomeranian Medical University, Szczecin, Poland
16 shared publications - Jacek Iwanowski
Department of Nuclear Medicine , Pomeranian Medical University in Szczecin , Szczecin , Poland
8 shared publications - Piotr Zorga
Department of Nuclear Medicine, Pomeranian Medical University, 1 Unii Lubelskiej Str., 71–252 Szczecin, Poland
7 shared publications Bogumiła Elbl
5 shared publications- Maria Chosia
Pomeranian Medical University in Szczecin
5 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Walter de Gruyter GmbH in Polish Journal of Medical Physics And Engineering
- Vol. 32 (3) , 138-145
Analysis of 177 Lu-DOTATATE injection methods and their impact on the exposure of hands of nuclear medicine facility staff
Purpose: The increasing use of peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE increases the need to assess occupational radiation exposure of nuclear medicine staff, particularly to the hands. This study aimed to evaluate and compare fingertip exposure associated with three administration methods: gravitational infusion, infusion pump, and manual injection. Materials and Methods: Dosimetric measurements were performed in two nuclear medicine centres using LiF:Mg,Cu,P thermoluminescent detectors placed on the fingertips and at the base of the middle finger of both hands of staff involved in radiopharmaceutical preparation and administration. Measurements were collected for physicists, radiopharmacists, nurses, and physicians. A total of 126 measurements were collected in four measurement sessions. The personal dose equivalent H p (0.07) was determined, normalised to administered activity (µSv/GBq), and analysed separately for preparation and administration procedures. Results: Manual administration resulted in the highest fingertip exposure, with maximum normalized H p (0.07) values of 26.95 µSv/GBq during preparation and 40.23 µSv/GBq during administration. Infusion pump administration showed intermediate exposure levels, while gravitational infusion yielded the lowest values, often close to the minimum detectable dose. Dominant hand fingertips, particularly the thumb and index finger, were most exposed. Estimated annual doses remained well below the skin dose limit. Conclusions: The administration technique significantly influences occupational hand exposure during 177 Lu- DOTATATE procedures. Manual administration leads to the highest doses, whereas gravitational and infusion pump methods substantially reduce staff exposure.
- 1 September 2026
- Published by Walter de Gruyter GmbH in Polish Journal of Medical Physics And Engineering
- Vol. 32 (3) , 138-145
Open AccessAnalysis of 177 Lu-DOTATATE injection methods and their impact on the exposure of hands of nuclear medicine facility staff
Purpose: The increasing use of peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE increases the need to assess occupational radiation exposure of nuclear medicine staff, particularly to the hands. This study aimed to evaluate and compare fingertip exposure associated with three administration methods: gravitational infusion, infusion pump, and manual injection. Materials and Methods: Dosimetric measurements were performed in two nuclear medicine centres using LiF:Mg,Cu,P thermoluminescent detectors placed on the fingertips and at the base of the middle finger of both hands of staff involved in radiopharmaceutical preparation and administration. Measurements were collected for physicists, radiopharmacists, nurses, and physicians. A total of 126 measurements were collected in four measurement sessions. The personal dose equivalent H p (0.07) was determined, normalised to administered activity (µSv/GBq), and analysed separately for preparation and administration procedures. Results: Manual administration resulted in the highest fingertip exposure, with maximum normalized H p (0.07) values of 26.95 µSv/GBq during preparation and 40.23 µSv/GBq during administration. Infusion pump administration showed intermediate exposure levels, while gravitational infusion yielded the lowest values, often close to the minimum detectable dose. Dominant hand fingertips, particularly the thumb and index finger, were most exposed. Estimated annual doses remained well below the skin dose limit. Conclusions: The administration technique significantly influences occupational hand exposure during 177 Lu- DOTATATE procedures. Manual administration leads to the highest doses, whereas gravitational and infusion pump methods substantially reduce staff exposure.
- Open Access
- 25 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 4952
Dosimetry in 177Lu-PRRT for Neuroendocrine Tumors: Current Concepts, Clinical Relevance and Future Perspectives
Background: Neuroendocrine tumors—are relatively rare but increasingly diagnosed malignancies originating from diffuse neuroendocrine cells, most commonly affecting the gastroenteropancreatic system. Due to their long asymptomatic development and low incidence, pose a diagnostic and therapeutic challenge for physicians. Recently, the role of nuclear medicine has been growing not only in the diagnostic stage but also in treatment. Systemic radionuclide therapy using somatostatin analogs labelled with the radioisotope lutetium-177 is becoming increasingly common in patients with advanced-stage disease. Currently, most patients receive a standard activity of therapeutic radiopharmaceuticals. Recent clinical studies provide increasing evidence of a close relationship between the absorbed radiation dose in pathological lesions and the therapeutic effect of radioisotope therapy. Internal dosimetry is used to measure the doses of ionising radiation absorbed by the patient after administration of the radiopharmaceutical. The lack of individual internal dosimetry prior to therapy means that only a small fraction of patients receive optimal doses of radioactivity, which is markedly different from external beam radiotherapy planning. Methods: A narrative literature review was conducted using the PubMed/MEDLINE and Embase databases, focusing primarily on publications from the last years. The search strategy included combinations of keywords related to peptide receptor radionuclide therapy and dosimetry, such as “Lutetium-177”, “neuroendocrine tumors”, “dosimetry”, “PRRT”, “systemic radionuclide therapy” and “artificial intelligence”. Particular emphasis was placed on recent prospective clinical studies, multicenter investigations, systematic reviews and consensus documents published by major nuclear medicine societies, including the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Seminal earlier publications considered essential for understanding the development of dosimetry concepts and clinical implementation were also included. Results: This study confirms the existence of a clinically significant dose-response relationship in 177Lu-PRRT. Higher absorbed doses to tumour lesions are associated with longer progression-free survival. The lack of individualized internal dosimetry prior to therapy means that only a small proportion of patients receive optimal radiation doses. Simplified dosimetric approaches with a reduced number of imaging time points, together with emerging artificial intelligence–based tools, appear promising for reducing the complexity of the dosimetry process. Conclusions: The aim of this study was to analyse the current literature on the role of internal dosimetry in the treatment of neuroendocrine tumors using the radioisotope lutetium-177. Available data support the clinical relevance of individualized dosimetry and highlight its potential to optimize both therapeutic efficacy and treatment safety.
- 25 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 4952
Open AccessDosimetry in 177Lu-PRRT for Neuroendocrine Tumors: Current Concepts, Clinical Relevance and Future Perspectives
Background: Neuroendocrine tumors—are relatively rare but increasingly diagnosed malignancies originating from diffuse neuroendocrine cells, most commonly affecting the gastroenteropancreatic system. Due to their long asymptomatic development and low incidence, pose a diagnostic and therapeutic challenge for physicians. Recently, the role of nuclear medicine has been growing not only in the diagnostic stage but also in treatment. Systemic radionuclide therapy using somatostatin analogs labelled with the radioisotope lutetium-177 is becoming increasingly common in patients with advanced-stage disease. Currently, most patients receive a standard activity of therapeutic radiopharmaceuticals. Recent clinical studies provide increasing evidence of a close relationship between the absorbed radiation dose in pathological lesions and the therapeutic effect of radioisotope therapy. Internal dosimetry is used to measure the doses of ionising radiation absorbed by the patient after administration of the radiopharmaceutical. The lack of individual internal dosimetry prior to therapy means that only a small fraction of patients receive optimal doses of radioactivity, which is markedly different from external beam radiotherapy planning. Methods: A narrative literature review was conducted using the PubMed/MEDLINE and Embase databases, focusing primarily on publications from the last years. The search strategy included combinations of keywords related to peptide receptor radionuclide therapy and dosimetry, such as “Lutetium-177”, “neuroendocrine tumors”, “dosimetry”, “PRRT”, “systemic radionuclide therapy” and “artificial intelligence”. Particular emphasis was placed on recent prospective clinical studies, multicenter investigations, systematic reviews and consensus documents published by major nuclear medicine societies, including the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Seminal earlier publications considered essential for understanding the development of dosimetry concepts and clinical implementation were also included. Results: This study confirms the existence of a clinically significant dose-response relationship in 177Lu-PRRT. Higher absorbed doses to tumour lesions are associated with longer progression-free survival. The lack of individualized internal dosimetry prior to therapy means that only a small proportion of patients receive optimal radiation doses. Simplified dosimetric approaches with a reduced number of imaging time points, together with emerging artificial intelligence–based tools, appear promising for reducing the complexity of the dosimetry process. Conclusions: The aim of this study was to analyse the current literature on the role of internal dosimetry in the treatment of neuroendocrine tumors using the radioisotope lutetium-177. Available data support the clinical relevance of individualized dosimetry and highlight its potential to optimize both therapeutic efficacy and treatment safety.
- Open Access
- 1 June 2025
- Published by Walter de Gruyter GmbH in Polish Journal of Medical Physics And Engineering
- Vol. 31 (2) , 104-109
How to experimentally test the accuracy of quantitative SPECT images?
Introduction: Radiopharmaceutical therapy (RPT) uses radiopharmaceuticals that target cancer cells and is increasingly used as an oncological treatment. Estimating the absorbed dose of ionizing radiation in the patient’s organs is the basis for personalized RPT. This article presents a technique for assessing the performance of a quantitative reconstruction using NEMA phantom. The goal of this work was to compare the accuracy of quantitative SPECT images using the same reconstruction algorithm but acquired with two different SPECT/CT systems from two different manufacturers. Materials and Methods: We performed a series of SPECT/CT acquisitions of a NEMA IEC Body Phantom filled with 177 Lu using two gamma cameras. The images were reconstructed and quantified using Hermes software. Results: There was no statistically significant difference in the results of recovered activities between the Symbia Intevo Bold and the NM/CT 850 gamma cameras. For a sphere with a diameter of 37 mm, the Rc values ranged from 0.69 to 0.75 for the Symbia Intevo Bold and 0.70 to 0.73 for the NM/CT 850. For a sphere with a diameter of 28 mm, the Rc values ranged from 0.61 to 0.71 for the Symbia Intevo Bold and 0.61 to 0.70 for the NM/CT 850. For a sphere with a diameter of 22 mm, the Rc values fell within the range of 0.56 to 0.63 for the Symbia Intevo Bold and 0.51 to 0.59 for the NM/CT 850. Conclusions: Quantitative SPECT images are necessary to perform dosimetry calculations and before using them in the clinical settings it is important to perform validation. This validation can be simply performed by acquiring images of the phantom filled with known activity using the same acquisition and reconstruction parameters as those employed for patients studies. In our study we observed comparable performance between images acquired by the systems from two different manufacturers.
- 1 June 2025
- Published by Walter de Gruyter GmbH in Polish Journal of Medical Physics And Engineering
- Vol. 31 (2) , 104-109
Open AccessHow to experimentally test the accuracy of quantitative SPECT images?
Introduction: Radiopharmaceutical therapy (RPT) uses radiopharmaceuticals that target cancer cells and is increasingly used as an oncological treatment. Estimating the absorbed dose of ionizing radiation in the patient’s organs is the basis for personalized RPT. This article presents a technique for assessing the performance of a quantitative reconstruction using NEMA phantom. The goal of this work was to compare the accuracy of quantitative SPECT images using the same reconstruction algorithm but acquired with two different SPECT/CT systems from two different manufacturers. Materials and Methods: We performed a series of SPECT/CT acquisitions of a NEMA IEC Body Phantom filled with 177 Lu using two gamma cameras. The images were reconstructed and quantified using Hermes software. Results: There was no statistically significant difference in the results of recovered activities between the Symbia Intevo Bold and the NM/CT 850 gamma cameras. For a sphere with a diameter of 37 mm, the Rc values ranged from 0.69 to 0.75 for the Symbia Intevo Bold and 0.70 to 0.73 for the NM/CT 850. For a sphere with a diameter of 28 mm, the Rc values ranged from 0.61 to 0.71 for the Symbia Intevo Bold and 0.61 to 0.70 for the NM/CT 850. For a sphere with a diameter of 22 mm, the Rc values fell within the range of 0.56 to 0.63 for the Symbia Intevo Bold and 0.51 to 0.59 for the NM/CT 850. Conclusions: Quantitative SPECT images are necessary to perform dosimetry calculations and before using them in the clinical settings it is important to perform validation. This validation can be simply performed by acquiring images of the phantom filled with known activity using the same acquisition and reconstruction parameters as those employed for patients studies. In our study we observed comparable performance between images acquired by the systems from two different manufacturers.
- Open Access
Individualization of Radionuclide Therapies: Challenges and Prospects
The article presents the problems of clinical implementation of personalized radioisotope therapy. The use of radioactive drugs in the treatment of malignant and benign diseases is rapidly expanding. Currently, in the majority of nuclear medicine departments worldwide, patients receive standard activities of therapeutic radiopharmaceuticals. Intensively conducted clinical trials constantly provide more evidence of a close relationship between the dose of radiopharmaceutical absorbed in pathological tissues and the therapeutic effect of radioisotope therapy. Due to the lack of individual internal dosimetry (based on the quantitative analysis of a series of diagnostic images) before or during the treatment, only a small fraction of patients receives optimal radioactivity. The vast majority of patients receive too-low doses of ionizing radiation to the target tissues. This conservative approach provides “radiation safety” to healthy tissues, but also delivers lower radiopharmaceutical activity to the neoplastic tissue, resulting in a low level of response and a higher relapse rate. The article presents information on the currently used radionuclides in individual radioisotope therapies and on radionuclides newly introduced to the therapeutic market. It discusses the causes of difficulties with the implementation of individualized radioisotope therapies as well as possible changes in the current clinical situation.
Open AccessIndividualization of Radionuclide Therapies: Challenges and Prospects
The article presents the problems of clinical implementation of personalized radioisotope therapy. The use of radioactive drugs in the treatment of malignant and benign diseases is rapidly expanding. Currently, in the majority of nuclear medicine departments worldwide, patients receive standard activities of therapeutic radiopharmaceuticals. Intensively conducted clinical trials constantly provide more evidence of a close relationship between the dose of radiopharmaceutical absorbed in pathological tissues and the therapeutic effect of radioisotope therapy. Due to the lack of individual internal dosimetry (based on the quantitative analysis of a series of diagnostic images) before or during the treatment, only a small fraction of patients receives optimal radioactivity. The vast majority of patients receive too-low doses of ionizing radiation to the target tissues. This conservative approach provides “radiation safety” to healthy tissues, but also delivers lower radiopharmaceutical activity to the neoplastic tissue, resulting in a low level of response and a higher relapse rate. The article presents information on the currently used radionuclides in individual radioisotope therapies and on radionuclides newly introduced to the therapeutic market. It discusses the causes of difficulties with the implementation of individualized radioisotope therapies as well as possible changes in the current clinical situation.
- Open Access
- 5 February 2022
- Published by Springer Nature in EJNMMI Physics
- Vol. 9 (1) , 1-20
What validation tests can be done by the clinical medical physicist while waiting for the standardization of quantitative SPECT/CT imaging?
Objective: The aim of the study was to assess the accuracy of quantitative SPECT/CT imaging in a clinical setting and to compare test results from two nuclear medicine departments. Methods: Phantom studies were carried out with two gamma cameras manufactured by GE Healthcare: Discovery NM/CT 670 and NM/CT 850, used in two nuclear medicine departments. The data were collected using a cylindrical uniform phantom and a NEMA/IEC NU2 Body Phantom, filled with 99mTc-pertechnetate. Results: The convergence of activity concentration recovery was validated for the two gamma cameras operating in two medical centers using the cylindrical uniform phantom. The comparison of results revealed a 5% difference in the background calibration factor Bg. cal; 6% difference in COV, and a 0.6% difference in total activity deviation ∆Atot. Recovery coefficients (RCmax) for activity concentration in spheres of the NEMA/IEC NU2 Body Phantom were measured for different image reconstruction techniques. RCmax was in the range of 0.2–0.4 for the smallest sphere (ϕ 10 mm), and 1.3–1.4 for the largest sphere (ϕ 37 mm). Conversion factors for SUVmax and SUVmean for the gamma camera systems used were 0.99 and 1.13, respectively. Conclusions: (1) Measurements taken in our study confirmed the clinical suitability of 5 parameters of image quality (Bg. cal—background calibration factor, ∆Atot—total activity deviation, COV—coefficient of variation used for image noise assessment, QH—hot contrast, AM—accuracy of measurements, or RC—recovery coefficient) for the validation of SPECT/CT system performance in terms of correct quantitative acquisitions of images. (2) This work shows that absolute SPECT/CT quantification is achievable in clinical nuclear medicine centers. Results variation of quantitative analyses between centers is mainly related to the use of different reconstruction methods. (3) It is necessary to standardize the technique of measuring the SUV conversion factor obtained with different SPECT/CT scanners.
- 5 February 2022
- Published by Springer Nature in EJNMMI Physics
- Vol. 9 (1) , 1-20
Open AccessWhat validation tests can be done by the clinical medical physicist while waiting for the standardization of quantitative SPECT/CT imaging?
Objective: The aim of the study was to assess the accuracy of quantitative SPECT/CT imaging in a clinical setting and to compare test results from two nuclear medicine departments. Methods: Phantom studies were carried out with two gamma cameras manufactured by GE Healthcare: Discovery NM/CT 670 and NM/CT 850, used in two nuclear medicine departments. The data were collected using a cylindrical uniform phantom and a NEMA/IEC NU2 Body Phantom, filled with 99mTc-pertechnetate. Results: The convergence of activity concentration recovery was validated for the two gamma cameras operating in two medical centers using the cylindrical uniform phantom. The comparison of results revealed a 5% difference in the background calibration factor Bg. cal; 6% difference in COV, and a 0.6% difference in total activity deviation ∆Atot. Recovery coefficients (RCmax) for activity concentration in spheres of the NEMA/IEC NU2 Body Phantom were measured for different image reconstruction techniques. RCmax was in the range of 0.2–0.4 for the smallest sphere (ϕ 10 mm), and 1.3–1.4 for the largest sphere (ϕ 37 mm). Conversion factors for SUVmax and SUVmean for the gamma camera systems used were 0.99 and 1.13, respectively. Conclusions: (1) Measurements taken in our study confirmed the clinical suitability of 5 parameters of image quality (Bg. cal—background calibration factor, ∆Atot—total activity deviation, COV—coefficient of variation used for image noise assessment, QH—hot contrast, AM—accuracy of measurements, or RC—recovery coefficient) for the validation of SPECT/CT system performance in terms of correct quantitative acquisitions of images. (2) This work shows that absolute SPECT/CT quantification is achievable in clinical nuclear medicine centers. Results variation of quantitative analyses between centers is mainly related to the use of different reconstruction methods. (3) It is necessary to standardize the technique of measuring the SUV conversion factor obtained with different SPECT/CT scanners.
- Open Access
- 25 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (17) , 3809
The Epidemiology and Clinical Presentations of Atopic Diseases in Selective IgA Deficiency
Selective IgA deficiency (sIgAD) is the most common primary immunodeficiency disease (PID), with an estimated occurrence from about 1:3000 to even 1:150, depending on population. sIgAD is diagnosed in adults and children after the 4th year of age, with immunoglobulin A level below 0.07 g/L and normal levels of IgM and IgG. Usually, the disease remains undiagnosed throughout the patient’s life, due to its frequent asymptomatic course. If symptomatic, sIgAD is connected to more frequent viral and bacterial infections of upper respiratory, urinary, and gastrointestinal tracts, as well as autoimmune and allergic diseases. Interestingly, it may also be associated with other PIDs, such as IgG subclasses deficiency or specific antibodies deficiency. Rarely sIgAD can evolve to common variable immunodeficiency disease (CVID). It should also be remembered that IgA deficiency may occur in the course of other conditions or result from their treatment. It is hypothesized that allergic diseases (e.g., eczema, rhinitis, asthma) are more common in patients diagnosed with this particular PID. Selective IgA deficiency, although usually mildly symptomatic, can be difficult for clinicians. The aim of the study is to summarize the connection between selective IgA deficiency and atopic diseases.
- 25 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (17) , 3809
Open AccessThe Epidemiology and Clinical Presentations of Atopic Diseases in Selective IgA Deficiency
Selective IgA deficiency (sIgAD) is the most common primary immunodeficiency disease (PID), with an estimated occurrence from about 1:3000 to even 1:150, depending on population. sIgAD is diagnosed in adults and children after the 4th year of age, with immunoglobulin A level below 0.07 g/L and normal levels of IgM and IgG. Usually, the disease remains undiagnosed throughout the patient’s life, due to its frequent asymptomatic course. If symptomatic, sIgAD is connected to more frequent viral and bacterial infections of upper respiratory, urinary, and gastrointestinal tracts, as well as autoimmune and allergic diseases. Interestingly, it may also be associated with other PIDs, such as IgG subclasses deficiency or specific antibodies deficiency. Rarely sIgAD can evolve to common variable immunodeficiency disease (CVID). It should also be remembered that IgA deficiency may occur in the course of other conditions or result from their treatment. It is hypothesized that allergic diseases (e.g., eczema, rhinitis, asthma) are more common in patients diagnosed with this particular PID. Selective IgA deficiency, although usually mildly symptomatic, can be difficult for clinicians. The aim of the study is to summarize the connection between selective IgA deficiency and atopic diseases.
- Open Access
- 19 August 2021
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 30 (9) , 913-921
Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves’ disease patients
The results of radioactive iodine (RAI) treatment for Graves' disease (GD) are related to the choice of diagnostic and dosimetry protocols, the steroid protection used, and the subsequent 131I dose. The effect of a high tissue-absorbed dose on the level of anti-thyroid antibodies (ATA) has been rarely considered. To estimate the effect of the first RAI therapy with a dose of 250 Gy on anti-thyreoperoxidase (anti-TPO) and anti-thyroid-stimulating hormone (TSH) receptor thyrotropin receptor antibody - TRAb levels in GD patients. The analysis encompassed 46 consecutive patients with clinical presentation of GD. We examined the serum levels of TSH, free thyroxine (FT4), anti-TPO, TRAb, thyroid volume (ThV), 131I effective half-life (EHL), introduction of steroid protection, levothyroxine dose used in thyroid replacement therapy - TRT, and effectiveness of treatment. As a result of RAI treatment, hypothyroidism was found in 35 patients (76.1%), euthyroidism in 7 patients (15.2%) and hyperthyroidism in 4 patients (8.7%). After RAI, we observed ThV reduction and increased anti-TPO (p = 0.001 and p = 0.001, respectively). It was found that a shorter EHL correlated with a higher baseline TRAb concentration and lower final anti-TPO serum concentration (p = 0.03 and p = 0.01, respectively). Lower final TRAb was found in patients with steroid protection (p = 0.049). Intergroup comparison of patients without steroid protection showed significantly higher final anti-TPO concentation (p = 0.02). Intergroup comparison of patients with TRT revealed significantly higher final anti-TPO concentration (p = 0.04). The application of a high absorbed dose of 250 Gy in GD resulted in high efficacy of RAI therapy at 1-year follow-up. An increased ATA level and its relationships with EHL and ThV reduction were observed at 1-year follow-up. There is a possible relationship between steroid protection and anti-TPO concentration.
- 19 August 2021
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 30 (9) , 913-921
Open AccessInfluence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves’ disease patients
The results of radioactive iodine (RAI) treatment for Graves' disease (GD) are related to the choice of diagnostic and dosimetry protocols, the steroid protection used, and the subsequent 131I dose. The effect of a high tissue-absorbed dose on the level of anti-thyroid antibodies (ATA) has been rarely considered. To estimate the effect of the first RAI therapy with a dose of 250 Gy on anti-thyreoperoxidase (anti-TPO) and anti-thyroid-stimulating hormone (TSH) receptor thyrotropin receptor antibody - TRAb levels in GD patients. The analysis encompassed 46 consecutive patients with clinical presentation of GD. We examined the serum levels of TSH, free thyroxine (FT4), anti-TPO, TRAb, thyroid volume (ThV), 131I effective half-life (EHL), introduction of steroid protection, levothyroxine dose used in thyroid replacement therapy - TRT, and effectiveness of treatment. As a result of RAI treatment, hypothyroidism was found in 35 patients (76.1%), euthyroidism in 7 patients (15.2%) and hyperthyroidism in 4 patients (8.7%). After RAI, we observed ThV reduction and increased anti-TPO (p = 0.001 and p = 0.001, respectively). It was found that a shorter EHL correlated with a higher baseline TRAb concentration and lower final anti-TPO serum concentration (p = 0.03 and p = 0.01, respectively). Lower final TRAb was found in patients with steroid protection (p = 0.049). Intergroup comparison of patients without steroid protection showed significantly higher final anti-TPO concentation (p = 0.02). Intergroup comparison of patients with TRT revealed significantly higher final anti-TPO concentration (p = 0.04). The application of a high absorbed dose of 250 Gy in GD resulted in high efficacy of RAI therapy at 1-year follow-up. An increased ATA level and its relationships with EHL and ThV reduction were observed at 1-year follow-up. There is a possible relationship between steroid protection and anti-TPO concentration.
- Open Access
- 9 August 2021
- Published by Springer Nature in Research Square
Optimised method for normal range estimation of standardized uptake values (SUVmax, SUVmean) in liver SPECT/CT images with somatostatin analogue 99mTc-HYNIC-TOC (Tektrotyd).
Background99mTc-HYNIC-TOC (Tektrotyd) is a radiopharmaceutical used for the diagnosis of lesions with overexpression of somatostatin receptors. The purpose of this study was to optimise the method and estimate normal ranges for standardized uptake values of Tektrotyd in healthy livers. MethodsAn analysis of SUVs normal ranges was performed for images acquired in a selected “healthy group” of 42 patients evaluated for NET tumours. The “pathological group” comprised 20 patients with liver lesions detected by scintigraphic imaging. Normal ranges for radiopharmaceutical uptake values were estimated based on the quantitative analysis of images acquired with a GE Healthcare NM/CT 850 gamma camera.ResultsThe method for healthy liver segmentation in SPECT/CT was optimized. The normal range of SUVs for the liver was: SUVbw max [5.2-14.0] g/ml and SUVlbm max [3.5-9.5] g/ml. The relative standard error (relative SE) of activity concentration estimated in the phantom study for the largest hot spheres was: ϕ=37mm- 5.9%, ϕ=28mm- 7.1%, ϕ=22mm- 11.4%, and ϕ=17mm- 22%.Conclusions· Segmentation in the mid-coronal CT image, at one-fourth of the height of the liver measured from the top, with a medium-sized VOI outlined on a given transverse SPECT slice was regarded as the optimal method for estimating normal ranges for standardized uptake values.· It is necessary to standardise quantification methods in the SPECT/CT studies. Our work is a step forward in obtaining standardisation of SPECT/CT SUV calculation methods.· Calculations for radiopharmaceutical uptake in tumours with volumes smaller than 5 ml are biased with a significant measurement error.
- 9 August 2021
- Published by Springer Nature in Research Square
Open AccessOptimised method for normal range estimation of standardized uptake values (SUVmax, SUVmean) in liver SPECT/CT images with somatostatin analogue 99mTc-HYNIC-TOC (Tektrotyd).
Background99mTc-HYNIC-TOC (Tektrotyd) is a radiopharmaceutical used for the diagnosis of lesions with overexpression of somatostatin receptors. The purpose of this study was to optimise the method and estimate normal ranges for standardized uptake values of Tektrotyd in healthy livers. MethodsAn analysis of SUVs normal ranges was performed for images acquired in a selected “healthy group” of 42 patients evaluated for NET tumours. The “pathological group” comprised 20 patients with liver lesions detected by scintigraphic imaging. Normal ranges for radiopharmaceutical uptake values were estimated based on the quantitative analysis of images acquired with a GE Healthcare NM/CT 850 gamma camera.ResultsThe method for healthy liver segmentation in SPECT/CT was optimized. The normal range of SUVs for the liver was: SUVbw max [5.2-14.0] g/ml and SUVlbm max [3.5-9.5] g/ml. The relative standard error (relative SE) of activity concentration estimated in the phantom study for the largest hot spheres was: ϕ=37mm- 5.9%, ϕ=28mm- 7.1%, ϕ=22mm- 11.4%, and ϕ=17mm- 22%.Conclusions· Segmentation in the mid-coronal CT image, at one-fourth of the height of the liver measured from the top, with a medium-sized VOI outlined on a given transverse SPECT slice was regarded as the optimal method for estimating normal ranges for standardized uptake values.· It is necessary to standardise quantification methods in the SPECT/CT studies. Our work is a step forward in obtaining standardisation of SPECT/CT SUV calculation methods.· Calculations for radiopharmaceutical uptake in tumours with volumes smaller than 5 ml are biased with a significant measurement error.
- Open Access
- 2 December 2020
- Published by Springer Nature in Research Square
What validation tests can be done by the clinical medical physicist while waiting for the standardization of quantitative SPECT/CT imaging?
Objective The aim of the study was to assess the accuracy of quantitative SPECT/CT imaging in a clinical setting and to compare test results from two nuclear medicine departments.Methods Phantom studies were carried out with two gamma cameras manufactured by GE Healthcare: Discovery NM/CT 670 and NM/CT 850, used in two nuclear medicine departments.Results The convergence of activity concentration recovery was validated for the two gamma cameras operating in two medical centres using a homogeneous 3D phantom. The comparison of results revealed a 5% difference in the calibration factor Bg. cal; 6% difference in COV, and a 0.6% difference in total activity deviation ∆Atot.Recovery coefficients (RCmax) for activity concentration in spheres of the anthropomorphic phantom was measured for different image reconstruction techniques. RCmax was in the range of 0.2-0.4 for the smallest sphere (ϕ10 mm), and 1.3-1.4 for the largest sphere (ϕ37 mm). Conversion factors for SUVmax and SUVmean for the gamma camera systems used were 0.99 and 1.13, respectively.Conclusions 1) Measurements taken in our study confirmed the clinical suitability of 5 parameters of image quality (Bg. cal- background calibration factor, ∆Atot- total activity deviation, COV- noise level estimation, QH- hot contrast, AM-accuracy of measurements or RC- recovery coefficient) for the validation of SPECT/CT system performance in terms of correct quantitative acquisitions of images. 2) This work shows that absolute SPECT/CT quantification is achievable in clinical nuclear medicine centers. Results variation of quantitative analyzes between centers is mainly related to the use of different reconstruction methods. 3) It is necessary to standardize the technique of measuring the SUV conversion factor obtained with different SPECT/CT scanners.
- 2 December 2020
- Published by Springer Nature in Research Square
Open AccessWhat validation tests can be done by the clinical medical physicist while waiting for the standardization of quantitative SPECT/CT imaging?
Objective The aim of the study was to assess the accuracy of quantitative SPECT/CT imaging in a clinical setting and to compare test results from two nuclear medicine departments.Methods Phantom studies were carried out with two gamma cameras manufactured by GE Healthcare: Discovery NM/CT 670 and NM/CT 850, used in two nuclear medicine departments.Results The convergence of activity concentration recovery was validated for the two gamma cameras operating in two medical centres using a homogeneous 3D phantom. The comparison of results revealed a 5% difference in the calibration factor Bg. cal; 6% difference in COV, and a 0.6% difference in total activity deviation ∆Atot.Recovery coefficients (RCmax) for activity concentration in spheres of the anthropomorphic phantom was measured for different image reconstruction techniques. RCmax was in the range of 0.2-0.4 for the smallest sphere (ϕ10 mm), and 1.3-1.4 for the largest sphere (ϕ37 mm). Conversion factors for SUVmax and SUVmean for the gamma camera systems used were 0.99 and 1.13, respectively.Conclusions 1) Measurements taken in our study confirmed the clinical suitability of 5 parameters of image quality (Bg. cal- background calibration factor, ∆Atot- total activity deviation, COV- noise level estimation, QH- hot contrast, AM-accuracy of measurements or RC- recovery coefficient) for the validation of SPECT/CT system performance in terms of correct quantitative acquisitions of images. 2) This work shows that absolute SPECT/CT quantification is achievable in clinical nuclear medicine centers. Results variation of quantitative analyzes between centers is mainly related to the use of different reconstruction methods. 3) It is necessary to standardize the technique of measuring the SUV conversion factor obtained with different SPECT/CT scanners.
- Open Access
- 24 October 2019
- Published by MDPI AG in Applied Sciences
- Vol. 9 (21) , 4511
Estimation of Parameters of Parathyroid Glands Using Particle Swarm Optimization and Multivariate Generalized Gaussian Function Mixture
The paper introduces a fitting method for Single-Photon Emission Computed Tomography (SPECT) images of parathyroid glands using generalized Gaussian function for quantitative assessment of preoperative parathyroid SPECT/CT scintigraphy results in a large patient cohort. Parathyroid glands are very small for SPECT acquisition and the overlapping of 3D distributions was observed. The application of multivariate generalized Gaussian function mixture allows modeling, but results depend on the optimization algorithm. Particle Swarm Optimization (PSO) with global best, ring, and random neighborhood topologies were compared. The obtained results show benefits of random neighborhood topology that gives a smaller error for 3D position and the position estimation was improved by about voxel size, but the most important is the reduction of processing time to a few minutes, compared to a few hours in relation to the random walk algorithm. Moreover, the frequency of obtaining low MSE values was more than two times higher for this topology. The presented method based on random neighborhood topology allows quantifying activity in a specific voxel in a short time and could be applied it in clinical practice.- 24 October 2019
- Published by MDPI AG in Applied Sciences
- Vol. 9 (21) , 4511
Open AccessEstimation of Parameters of Parathyroid Glands Using Particle Swarm Optimization and Multivariate Generalized Gaussian Function Mixture
The paper introduces a fitting method for Single-Photon Emission Computed Tomography (SPECT) images of parathyroid glands using generalized Gaussian function for quantitative assessment of preoperative parathyroid SPECT/CT scintigraphy results in a large patient cohort. Parathyroid glands are very small for SPECT acquisition and the overlapping of 3D distributions was observed. The application of multivariate generalized Gaussian function mixture allows modeling, but results depend on the optimization algorithm. Particle Swarm Optimization (PSO) with global best, ring, and random neighborhood topologies were compared. The obtained results show benefits of random neighborhood topology that gives a smaller error for 3D position and the position estimation was improved by about voxel size, but the most important is the reduction of processing time to a few minutes, compared to a few hours in relation to the random walk algorithm. Moreover, the frequency of obtaining low MSE values was more than two times higher for this topology. The presented method based on random neighborhood topology allows quantifying activity in a specific voxel in a short time and could be applied it in clinical practice.